These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 24134531)

  • 1. Efficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: a systematic review.
    Zhang C; Wen J; Li Z; Fan J
    BMC Nephrol; 2013 Oct; 14():226. PubMed ID: 24134531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Ruospo M; Palmer SC; Natale P; Craig JC; Vecchio M; Elder GJ; Strippoli GF
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006023. PubMed ID: 30132304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
    Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
    Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and effectiveness of lanthanum carbonate for hyperphosphatemia in chronic kidney disease (CKD) patients: a meta-analysis.
    Zhao L; Liu A; Xu G
    Ren Fail; 2021 Dec; 43(1):1378-1393. PubMed ID: 34602015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: A systematic review and NMA.
    Sekercioglu N; Angeliki Veroniki A; Thabane L; Busse JW; Akhtar-Danesh N; Iorio A; Cruz Lopes L; Guyatt GH
    PLoS One; 2017; 12(3):e0171028. PubMed ID: 28248961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A meta-analysis of phosphate binders lanthanum carbonate versus sevelamer hydrochloride in patients with end-stage renal disease undergoing hemodialysis.
    Zhou T; Li H; Xie W; Lin Z
    Afr Health Sci; 2018 Sep; 18(3):689-696. PubMed ID: 30603002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of lanthanum carbonate versus calcium-based phosphate binders in patients with chronic kidney disease: a systematic review and meta-analysis.
    Zhai CJ; Yang XW; Sun J; Wang R
    Int Urol Nephrol; 2015 Mar; 47(3):527-35. PubMed ID: 25399356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dietary interventions for mineral and bone disorder in people with chronic kidney disease.
    Liu Z; Su G; Guo X; Wu Y; Liu X; Zou C; Zhang L; Yang Q; Xu Y; Ma W
    Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD010350. PubMed ID: 26376110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of lanthanum carbonate on coronary artery calcification and bone mineral density in maintenance hemodialysis patients with diabetes complicated with adynamic bone disease: A prospective pilot study.
    Zhang C; Wang S; Zhao S; Zhang X
    Medicine (Baltimore); 2017 Nov; 96(45):e8664. PubMed ID: 29137107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study.
    Toida T; Fukudome K; Fujimoto S; Yamada K; Sato Y; Chiyotanda S; Kitamura K
    Clin Nephrol; 2012 Sep; 78(3):216-23. PubMed ID: 22874110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients.
    D'Haese PC; Spasovski GB; Sikole A; Hutchison A; Freemont TJ; Sulkova S; Swanepoel C; Pejanovic S; Djukanovic L; Balducci A; Coen G; Sulowicz W; Ferreira A; Torres A; Curic S; Popovic M; Dimkovic N; De Broe ME
    Kidney Int Suppl; 2003 Jun; (85):S73-8. PubMed ID: 12753271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of aortic calcification with lanthanum carbonate vs. calcium-based phosphate binders in maintenance hemodialysis patients with type 2 diabetes mellitus: an open-label randomized controlled trial.
    Wada K; Wada Y
    Ther Apher Dial; 2014 Aug; 18(4):353-60. PubMed ID: 24417760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A meta-analysis of randomized controlled trials of tonifying kidney and strengthen bone therapy on nondialysis patients with chronic kidney disease-mineral and bone disorder.
    Wu G; Li L; Wu Z
    Medicine (Baltimore); 2023 Jun; 102(25):e34044. PubMed ID: 37352066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
    Patel L; Bernard LM; Elder GJ
    Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Restoration of parathyroid function after change of phosphate binder from calcium carbonate to lanthanum carbonate in hemodialysis patients with suppressed serum parathyroid hormone.
    Inaba M; Okuno S; Nagayama H; Yamada S; Ishimura E; Imanishi Y; Shoji S
    J Ren Nutr; 2015 Mar; 25(2):242-6. PubMed ID: 25556148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Lanthanum Carbonate on All-Cause Mortality in Patients Receiving Maintenance Hemodialysis: a Meta-Analysis of Randomized Controlled Trials.
    Wang F; Lu X; Zhang J; Xiong R; Li H; Wang S
    Kidney Blood Press Res; 2018; 43(2):536-544. PubMed ID: 29627829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of lanthanum carbonate on bone markers and bone mineral density in incident hemodialysis patients.
    Goto K; Goto S; Fujii H; Watanabe K; Kono K; Nishi S
    J Bone Miner Metab; 2019 Nov; 37(6):1075-1082. PubMed ID: 31214836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.
    Prajapati VA; Galani VJ; Shah PR
    Saudi J Kidney Dis Transpl; 2014 May; 25(3):530-8. PubMed ID: 24821148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open-label phase 2 trial to assess the efficacy, safety and pharmacokinetics of lanthanum carbonate in hyperphosphatemic children and adolescents with chronic kidney disease undergoing dialysis.
    Wasilewska A; Murray RA; Sundberg A; Uddin S; Achenbach H; Shavkin A; Szabó T; Vergani A; Umeh O
    BMC Nephrol; 2022 Mar; 23(1):84. PubMed ID: 35236302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.